Quick Answer
Elanco Animal Health Inc reported Total Revenue of $4.71 billion for fiscal year 2025.
Elanco Animal Health Inc — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $4.71B +6.2% |
$4.44B +0.5% |
$4.42B +0.1% |
$4.41B -7.4% |
$4.76B | — |
| Revenue (ASC 606) | $4.71B +6.2% |
$4.44B +0.5% |
$4.42B +0.1% |
$4.41B -7.4% |
$4.76B | — |
| Net Income | -$232.00M -168.6% |
$338.00M +127.5% |
-$1.23B -1478.2% |
-$78.00M +83.9% |
-$483.00M +15.9% |
-$574.00M -944.1% |
| Diluted EPS | -$0.47 -169.1% |
$0.68 +127.2% |
-$2.50 -1462.5% |
-$0.16 +83.8% |
-$0.99 +23.8% |
-$1.30 -822.2% |
| Total Assets | $13.36B +5.9% |
$12.61B -12.2% |
$14.36B -7.3% |
$15.49B -6.0% |
$16.48B -6.9% |
$17.69B +96.9% |
| Cash and Equivalents | $545.00M +16.5% |
$468.00M +33.0% |
$352.00M +2.0% |
$345.00M -45.9% |
$638.00M +28.9% |
$495.00M +48.2% |
| Long-Term Debt | — | $4.28B -25.4% |
$5.74B +5.3% |
$5.45B -9.6% |
$6.03B +8.1% |
$5.57B +139.1% |
| Stockholders Equity | $6.55B +7.4% |
$6.10B -2.0% |
$6.22B -14.6% |
$7.29B -2.9% |
$7.51B -11.2% |
$8.46B +52.6% |
| R&D Expense | $368.00M +7.0% |
$344.00M +5.2% |
$327.00M +1.9% |
$321.00M -13.0% |
$369.00M +12.2% |
$329.00M +21.9% |
| Gross Profit | $2.59B +6.4% |
$2.44B -2.0% |
$2.49B | — | — | — |
| Shares Outstanding | 496.98M +0.5% |
494.45M +0.3% |
492.85M +3.9% |
474.24M +0.2% |
473.12M +0.3% |
471.92M +26.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $1.14B | +10.4% | -8.4% |
| Revenue (ASC 606) | September 30, 2025 | $1.14B | +10.4% | -8.4% |
| Net Income | September 30, 2025 | -$34.00M | -109.3% | -409.1% |
| Diluted EPS | September 30, 2025 | -$0.07 | -109.6% | -450.0% |
| Total Assets | September 30, 2025 | $13.55B | +2.0% | -1.4% |
| Cash and Equivalents | September 30, 2025 | $505.00M | +3.1% | -6.3% |
| Long-Term Debt | March 31, 2025 | $4.35B | -24.0% | +1.7% |
| Stockholders Equity | September 30, 2025 | $6.75B | +3.5% | -0.4% |
| R&D Expense | September 30, 2025 | $89.00M | +2.3% | -3.3% |
| Gross Profit | September 30, 2025 | $607.00M | +12.8% | -14.9% |
| Shares Outstanding | September 30, 2025 | 496.83M | +0.5% | +0.0% |
- Elanco Animal Health Inc reported Total Revenue of $4.71 billion for fiscal year 2025.
- Elanco Animal Health Inc showed an increase of +6.2% in Total Revenue compared to the prior fiscal year.
- Elanco Animal Health Inc reported Revenue (ASC 606) of $4.71 billion for fiscal year 2025.
- Elanco Animal Health Inc showed an increase of +6.2% in Revenue (ASC 606) compared to the prior fiscal year.
- Elanco Animal Health Inc reported Net Income of -$232.00 million for fiscal year 2025.
- Elanco Animal Health Inc showed a decrease of -168.6% in Net Income compared to the prior fiscal year.
- Elanco Animal Health Inc reported Diluted EPS of $0.47 per share (loss) for fiscal year 2025.
- Elanco Animal Health Inc showed a decrease of -169.1% in Diluted EPS compared to the prior fiscal year.
- Elanco Animal Health Inc reported Total Assets of $13.36 billion for fiscal year 2025.
- Elanco Animal Health Inc showed an increase of +5.9% in Total Assets compared to the prior fiscal year.
- Elanco Animal Health Inc reported Cash and Equivalents of $545.00 million for fiscal year 2025.
- Elanco Animal Health Inc showed an increase of +16.5% in Cash and Equivalents compared to the prior fiscal year.
- Elanco Animal Health Inc reported Long-Term Debt of $4.28 billion for fiscal year 2024.
- Elanco Animal Health Inc showed a decrease of -25.4% in Long-Term Debt compared to the prior fiscal year.
- Elanco Animal Health Inc reported Stockholders Equity of $6.55 billion for fiscal year 2025.
- Elanco Animal Health Inc showed an increase of +7.4% in Stockholders Equity compared to the prior fiscal year.
- Elanco Animal Health Inc reported R&D Expense of $368.00 million for fiscal year 2025.
- Elanco Animal Health Inc showed an increase of +7.0% in R&D Expense compared to the prior fiscal year.
- Elanco Animal Health Inc reported Gross Profit of $2.59 billion for fiscal year 2025.
- Elanco Animal Health Inc showed an increase of +6.4% in Gross Profit compared to the prior fiscal year.
- Elanco Animal Health Inc reported Shares Outstanding of 496.98 million shares for fiscal year 2025.
- Elanco Animal Health Inc showed an increase of +0.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: